In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on Arcutis Biotherapeutics (ARQT – Research Report). The company’s shares closed today at $3.54.
According to TipRanks, Shibutani is a 5-star analyst with an average return of 14.3% and a 45.43% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Neurocrine, and Bristol-Myers Squibb.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcutis Biotherapeutics with a $11.75 average price target.
See the top stocks recommended by analysts >>
Based on Arcutis Biotherapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $38.11 million and a GAAP net loss of $44.77 million. In comparison, last year the company earned a revenue of $725 thousand and had a GAAP net loss of $107.71 million
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARQT in relation to earlier this year. Last month, Watanabe Todd Franklin, the Reporting Person’s title: CEO and President of ARQT bought 59,525.00 shares for a total of $100,002.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcutis Biotherapeutics (ARQT) Company Description:
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Read More on ARQT:
- Arcutis Biotherapeutics announces new individual patient response data
- Arcutis Biotherapeutics announces new subgroup analysis from STRATUM study
- Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
- ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
- Largest borrow rate increases among liquid names
